FLXN

Flexion Therapeutics, Inc. [FLXN] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

FLXN Stock Summary

Top 10 Correlated ETFs

FLXN

Top 10 Correlated Stocks

FLXN

In the News

FLXN Financial details

Company Rating
-
Market Cap
0
Income
-100.72M
Revenue
100.4M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
257
Optionable
No
Shortable
Yes
Earnings
12 Nov 2021
P/E
-3.43
Forward P/E
-
PEG
0.72
P/S
-
P/B
-23.42
P/C
-
P/FCF
-
Quick Ratio
3.72
Current Ratio
4.09
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.07
EPS next Y
-
EPS next Q
-
EPS this Y
-32.32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-24.31%
EPS Q/Q
36.36%
-
-
-
-
SMA20
0.27%
SMA50
1.7%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-45%
ROE
619%
ROC
-0.47%
Gross Margin
78%
Oper. Margin
-109%
Profit Margin
-133%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.12-9.225
52W High
+185.56%
52W Low
+185.56%
RSI
54.13
Rel Volume
-
Avg Volume
2.17M
Volume
1.03K
Perf Week
0.08%
Perf Month
0.23%
Perf Quarter
-
Perf Half Y
3.05%
-
-
-
-
Beta
1.52727
-
-
Volatility
0.06%, 0.09%
Prev Close
-0.12%
Price
25.7
Change
-0.43%

Something similar

Top by Market Cap
BRK-A
BRH.DE
0YXG.L
VOO
BRK-B
Top Correlated ETFs
DGRW
MFUS
DTD
DVND
SCHV
Top Correlated Stocks
GTCSX
GTSCX
THR
PH
FIVE
Similar Market Cap
CDK
SEUPX
PERI.TA
2170.T
2363.TW

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.